Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc. (NASDAQ:BIIB) shares came under pressure Friday after the Food and Drug Administration called for an investigation into the approval of the company's Alzheimer's treatment Aduhelm. What Happened: In a letter disclosed publicly, FDA Acting Commissioner Janet Woodcock requested the office of the inspector general at the Department of Health and Human Services review and assess the interactions between representatives of Biogen and the FDA in the run up to the approval of the biologic license application for Aduhelm.

FDA Requests Probe Into Staff Interactions With Biogen Ahead Of Aduhelm Approval

“There continue to be concerns raised … regarding contacts between representatives from Biogen and FDA during the review process,” the acting commissioner wrote to acting Inspector General Christi Grimm.

FDA calls for federal investigation into approval of Alzheimer's drug

The acting commissioner of the Food and Drug Administration has called for a government investigation into her own agency's approval of Biogen's new Alzheimer's disease drug.

FDA calls for investigation into its own approval of Biogen's Alzheimer's drug

Acting FDA Commissioner Woodcock asked the independent Office of the Inspector General to investigate interactions between the agency and Biogen prior to the drug's approval.

Biogen stock falls after FDA calls for federal investigation into Alzheimer's drug approval

Biogen stock falls as FDA may investigate Alzheimer's drug approval process

The FDA approves label update for Biogen's (BIIB) new Alzheimer's drug, Aduhelm. The updated label narrows the patient population, which is eligible for the drug.

Biogen (BIIB) Gets FDA Nod for Narrow Label of Aduhelm

The company faces hard questions from a House committee about the pricing of Alzheimer's disease drug Aduhelm.

Should Biogen Worry About a Congressional Investigation Into Its Alzheimer's Disease Drug?

CAMBRIDGE, Mass. and NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Today, access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. These genetic data have been paired with detailed health information to create this browsable resource.

Collaboration Between AbbVie, Biogen and Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease

Amazon

Intel

The broader averages are doing great, but buying and shorting these 3 blue-chip stocks is a calculated way to beat the market. The post 3 Blue-Chip Stocks to Trade Right Now appeared first on InvestorPlace.

3 Blue-Chip Stocks to Trade Right Now

Golden Nugget Online Gaming

Even with markets suffering, there were still some positives on Wall Street.

Forget a Bear Market -- These 2 Nasdaq Stocks Are Moving Higher

Biogen Inc. (NASDAQ:BIIB) shares are lower after the company announced an updated label for its recently-approved Alzheimer's treatment Aduhelm. What Happened: Biogen, which is partnering with Japan's Eisai Co., Ltd.

FDA Narrows Label To Recommend Use Of Biogen's Aduhelm In Mild Alzheimer's Patients

Shares of Biogen Inc. were down 3.6% in premarket trading on Thursday after the company updated the label for its new Alzheimer's disease treatment, Aduhelm. The Food and Drug Administration approved the label update, which now says that the therapy should be used in patients with "mild cognitive impairment or mild dementia stage of disease" because that is the group of people who were studied in the clinical trials.

Biogen updates label for Alzheimer's disease drug to say it should be used in people with 'mild' disease

ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia

FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials

Eli Lilly

An unusually lenient FDA is a knife that cuts both ways for Biogen.

Is Eli Lilly a Better Alzheimer's Stock Than Biogen?

Biogen's Alzheimer's drug approval creates major controversy. Effects of this approval on other companies and the Alzheimer's drug market are discussed.

Biogen Controversy And The Spillover Effect: Actionable Insights

Amgen

BioNTech SE

Moderna

Intellia Therapeutics

Regeneron Pharmaceuticals

Repligen

Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.

3 Biotech Stocks Poised to Gain in the Second Half of 2021

Netflix

Tesla

Who's right: the bulls or the bears? You'll need to make the final call.

Wall Street Is Completely Clueless About These 3 Popular Stocks

A nonprofit group doesn't like a recent move by Biogen.

How Biogen Made an Enemy of 1 of the Biggest Supporters of Its Alzheimer's Disease Drug

These drug stocks are in competition with Biogen for an Alzheimer's treatment, and can break out in a similar fashion offering better value. The post 3 Better Alzheimer's Drug Stocks to Buy Instead of Biogen appeared first on InvestorPlace.

3 Better Alzheimer's Drug Stocks to Buy Instead of Biogen

The stock price of Biogen has seen a 10% drop over the last five trading days. BIIB stock has seen a massive rally from levels of $267 in early June to around $380 last week, before dropping to $348 currently.

What's Next For Biogen Stock After A 10% Fall Last Week Amid Recent Controversy?

Enel X Collaborates With Biogen To Electrify Take-home Vehicle Fleet In North America

Could Biogen's Big Win With Aduhelm Become a Big Liability?

The drugmaker has had one big clinical setback and another less serious disappointment in recent weeks.

How Bad Is Biogen's Latest Bad News?

The recent approval of Biogen Inc's (NASDAQ: BIIB) high-price Alzheimer's drug is raising questions about who will have access to the $56,000/year treatment that could cost Medicare billions of dollars in coming years. Medicare typically pays unconditionally for approved medicines, but to limit the financial hit from Aduhelm, however, Medicare could restrict access, the Wall Street Journal reported.

Biogen's Costly Alzheimer's Treatment May Face Restricted Medicare Access: WSJ

BIIB stock was boosted when its Alzheimer's drug was approved. The company's strong financials can sustain the stock's growth.

News for Biogen Stock (BIIB)